Relay Therapeutics

Relay Therapeutics

RLAY· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +105.3% in FY2025

Sanjiv K. Patel, M.D. is the CEO of Relay Therapeutics and was paid $4.6M in FY2025 (Dec), down 64%.

Pay$100 in the stock at the end of FY20 → $20
CEO pay is from each Relay Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Sanjiv K. Patel, M.D.FY2025
  2. 2Donald Bergstrom, M.D., Ph.D.FY2025
  3. 3Thomas CatinazzoFY2025
  4. 4Peter RahmerFY2025
  5. 5Brian R. AdamsFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Relay Therapeutics paid its 5 named executives $11.0M in total in FY2025 (Dec). CEO Sanjiv K. Patel, M.D. was paid $4.6M of that.

Name
Sanjiv K. Patel, M.D.President and Chief Executive Officer
Donald Bergstrom, M.D., Ph.D.President, Research & Development
Thomas CatinazzoChief Financial Officer
Peter RahmerChief Corporate Development Officer
Brian R. AdamsFormer Chief Legal Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers22

See all

The FY2025 (Dec) proxy of Relay Therapeutics names 22 peer companies for pay. Among Relay Therapeutics and these peers, CEO pay was 11th highest of 13 and total shareholder return was 9th highest of 12.

11th highest of 13in Relay Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$2.8M$27.8M

9th highest of 12in Relay Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$14$414

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Sekar Kathiresan, M.D.Director · 3 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Habib Joseph DableDirector · 0 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Lonnel CoatsDirector · 0 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Relay Therapeutics CFO pay fell 64% to $1.6M. The stock rose 105% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Relay Therapeutics CEO pay fell 64% to $4.6M. The stock rose 105% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Relay Therapeutics Chief Corporate Development Officer pay fell 69% to $1.5M. The stock rose 105% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Relay Therapeutics Division head pay fell 68% to $2.1M. The stock rose 105% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Relay Therapeutics General counsel pay fell 73% to $1.2M. The stock rose 105% in FY2025 (Dec).
    DEF 14A
  6. Board
    Lonnel Coats joined the board of Relay Therapeutics. Lonnel Coats sits on no other public board.
    3
  7. Board
    Habib Joseph Dable joined the board of Relay Therapeutics. Habib Joseph Dable sits on no other public board.
    3
  8. Pay
    Relay Therapeutics CFO pay fell 16% to $4.4M. The stock fell 63% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Relay Therapeutics CEO pay fell 34% to $13.1M. The stock fell 63% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Relay Therapeutics Chief Corporate Development Officer pay fell 27% to $5.0M. The stock fell 63% in FY2024 (Dec).
    DEF 14A
  11. Pay
    Relay Therapeutics Division head pay fell 23% to $6.6M. The stock fell 63% in FY2024 (Dec).
    DEF 14A
  12. Pay
    Relay Therapeutics CFO pay rose 112% to $5.2M. The stock fell 26% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Relay Therapeutics CFO pay rose 34% to $2.5M. The stock fell 51% in FY2022 (Dec).
    DEF 14A
  14. Pay
    Relay Therapeutics CEO pay rose 143% to $19.8M. The stock fell 26% in FY2023 (Dec).
    DEF 14A
  15. Pay
    Relay Therapeutics Chief Corporate Development Officer pay rose 179% to $6.8M. The stock fell 26% in FY2023 (Dec).
    DEF 14A
  16. Pay
    Relay Therapeutics Division head pay rose 127% to $8.6M. The stock fell 26% in FY2023 (Dec).
    DEF 14A
  17. Pay
    Relay Therapeutics General counsel pay rose 84% to $4.5M. The stock fell 26% in FY2023 (Dec).
    DEF 14A
  18. Pay
    Relay Therapeutics General counsel pay rose 30% to $2.5M. The stock fell 51% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 23, 2025FY2024
Annual report10-KFeb 26, 2025FY2024
Proxy statementDEF 14AApr 23, 2024FY2023
Annual report10-KFeb 22, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data